Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with a loss of less than 3 Snellen lines (which is equivalent to less than 0.3 logMAR) of visual acuity within the past 12 months. First performance rate used for reporting.